REVIEWING THE DYSREGULATION OF ADAMTS13 AND VWF IN SEPSIS

被引:2
|
作者
Madarati, Hasam
Singh, Kanwal
Sparring, Taylor
Andrisani, Peter
Liaw, Patricia C.
Fox-Robichaud, Alison E.
Kretz, Colin A.
机构
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada
来源
SHOCK | 2024年 / 61卷 / 02期
关键词
ADAMTS13; Von Willebrand factor; sepsis; disseminated intravascular coagulation; hemostasis; coagulation; cardiovascular disease; thrombotic microangiopathies; thrombotic thrombocytopenia purpura; Von Willebrand disease; inflammation; neutrophil extracellular traps; alpha-defensin; VON-WILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; MYOCARDIAL-INFARCTION; ISCHEMIC-STROKE; INTRAVASCULAR COAGULATION; INFLAMMATORY CYTOKINES; CLINICAL-IMPLICATIONS; ENDOTHELIAL-CELLS; FACTOR PROPEPTIDE;
D O I
10.1097/SHK.0000000000002291
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Sepsis is defined as a life-threatening organ dysfunction caused by excessive host response to infection, and represents the most common cause of in-hospital deaths. Sepsis accounts for 30% of all critically ill patients in the intensive care unit (ICU), and has a global mortality rate of 20%. Activation of blood coagulation during sepsis and septic shock can lead to disseminated intravascular coagulation, which is characterized by microvascular thrombosis. Von Willebrand factor (VWF) and ADAMTS13 are two important regulators of blood coagulation that may be important links between sepsis and mortality in the ICU. Herein we review our current understanding of VWF and ADAMTS13 in sepsis and other critical illnesses and discuss their contribution to disease pathophysiology, their use as markers of severe illness, and potential targets for new therapeutic development.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 50 条
  • [1] The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction
    Austin, S. K.
    Starke, R. D.
    Lawrie, A. S.
    Cohen, H.
    Machin, S. J.
    Mackie, I. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (04) : 536 - 544
  • [2] ADAMTS13 cleavage of VWF
    Lane, D. A.
    HAEMOPHILIA, 2012, 18 : 107 - 107
  • [3] ADAMTS13: dynamic interactions with VWF
    Lane, D. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 63 - 64
  • [4] ADAMTS13 activity, ADAMTS13 and vWF Antigen concentration and the risk of myocardial infarction
    Vetr, H.
    Geiter, S.
    Graf, M.
    Laemmle, B.
    Redondo, M.
    Binder, B. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 563 - 563
  • [5] VWF, ADAMTS13, and acute coronary syndromes
    Kleiman, Neal S.
    BLOOD, 2016, 127 (23) : 2788 - 2789
  • [6] ADAMTS13 and VWF: not just for TTP anymore?
    Desch, K
    Motto, D
    BLOOD, 2005, 106 (13) : 4024 - 4024
  • [7] Plasma modifiers of VWF cleavage by ADAMTS13
    Tsai, H-M
    Zhou, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 27 - 27
  • [8] Genetic Modifiers of VWF Cleavage by ADAMTS13
    Zhou, Wenhua
    Tsai, Han-Mou
    BLOOD, 2008, 112 (11) : 107 - 107
  • [9] The application of vWF/ADAMTS13 in essential hypertension
    Ma, Wei-Hong
    Sheng, Lin
    Gong, Hui-Ping
    Guo, Lin-Lin
    Lu, Qing-Hua
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 7 (12): : 5636 - 5642
  • [10] Update on ADAMTS13 and VWF in cardiovascular and hematological disorders
    Akyol, Omer
    Akyol, Sumeyya
    Chen, Chu-Huang
    CLINICA CHIMICA ACTA, 2016, 463 : 109 - 118